AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04641351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zilretta Injectable Product or Placebo
Description: The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
Study NCT04641351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilretta Injectable Product or Placebo
Description: The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
Study NCT06254833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: micro dosing of ICG
Description: smaller dose of injection of ICG. All devices used are FDA approved in clinical use.
Study NCT05462704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
Study NCT05462704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: 325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
Study NCT06564090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robot assisted gait training
Description: Morning Walk® is a new end-effector type robot developed by Hyundai Heavy Industries and Taeha Mechatronics for lower limb rehabilitation in the patients with gait disturbance.The RAGT group received RAGT with robot training for 30 minutes and conventional physiotherapy for 30 minutes per session.
Study NCT06564090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional gait training
Description: The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
Study NCT06564090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional gait training
Description: The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
Study NCT04641026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli sprouts
Description: Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
Study NCT04641026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deuterium oxide-labelled broccoli sprouts
Description: Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
Study NCT04641026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alfalfa sprouts
Description: Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
Study NCT04641026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Deuterium oxide-labelled alfalfa sprouts
Description: Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
Study NCT05775939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given FDG
Study NCT05775939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT05775939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT
Study NCT05775939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04874012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator Taurine
Description: Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
Study NCT04874012 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle
Study NCT04905888 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Subjects randomized to treatment will receive up to ten 90 minute treatments with hyperbaric oxygen over a 2-3 week period.
Study NCT05475561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Pecto-intercostal- fascial plane block
Description: The probe of the ultrasound will be placed at 2 cm lateral to the lateral sternal border at 5th and 6th rib. On the surface plane subcutaneous tissue is identified, while Pectoralis major muscle, Intercostal muscles and ribs are seen in intermediate plane and lung along with pleura are identified in deep plane. A 22-gauge, 80-mm short bevel echogenic needle is used and advanced in in-plane manner, in a caudal-to-cranial direction, until the tip of the needle is located in the fascial plane between the pectoralis major and internal intercostal muscle, where the local anesthetic will be injected.
Study NCT05475561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided erector spinae plane block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. Three muscles trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Local infiltration with 2% of lignocaine at the site of needle insertion will be done. Using in-plane approach a 22 G short bevel needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro dissection below the muscle plane. A 20 ml of 0.25% plain bupivacaine will be injected on each side.
Study NCT05475561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: local anesthetic
Study NCT04432025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery + goal directed medical therapy
Description: Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
Study NCT04432025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
Study NCT05888428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoTrain
Description: MyoTrain is a virtual prosthesis control training system. From a hardware perspective it consists of an Apple iPad tablet computer and an eight-channel EMG armband, based on the Element electrode platform, which interfaces with the tablet via Bluetooth™. From a software perspective, MyoTrain was developed in the cross-platform Unity 4.0 game development environment.
Study NCT05888428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery
Description: Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
Study NCT06412406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Oblique Intercostal (EOI) block
Description: EOI block technique A linear ultrasound transducer placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, The transducer was then rotated so the cranial end was directed slightly medially and the caudal end laterally to produce a paramedian sagittal oblique view with a short-axis view of the ribs, The following structures were identified, from superficial to deep: subcutaneous tissue, external oblique muscle, intercostal muscles between ribs, pleura, and lung. The skin entry point for the injection was cranial to the sixth rib level just medial to the anterior axillary line, with ultrasound opaque needle advanced in plane from a superomedial-to-inferolateral direction, through the external oblique muscle hydrodissecting the tissue plane between the sixth and seventh ribs, and then the needle was directed caudally toward the eighth rib. and inject 20 ml volume of (0.25 % bupivacaine).
Study NCT06412406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: TAP block technique:~abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest (18) . Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. and ingect 20 ml volume of (0.25 % bupivacaine). If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study.
Study NCT05617027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: actual transcranial direct current stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms.~The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA.
Study NCT05617027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo transcranial direct current stimulation (tDCS)
Description: The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.
Study NCT05839548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine 2% with epinephrine 1:100,000
Description: Local Anesthesia
Study NCT05839548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine (4%) with epinephrine 1:100,000
Description: Local Anesthesia
Study NCT06022640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and supportive care
Description: The trial had a total of 75 participants assigned to the intervention group, whereby they were provided with an educative and supporting program specifically developed by a clinical pharmacist. The intervention group was provided with assistance via a series of five visits, which included an initial visit upon admission, subsequent visits for monitoring medication, ovulation, and negative effects, as well as visits dedicated to giving emotional support. Additionally, a follow-up visit was conducted after the egg collecting process and embryo transfer.
Study NCT06556199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.
Study NCT06556199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.
Study NCT06556199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).
Study NCT05773612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rock Steady Boxing Class
Description: Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
Study NCT05140564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEADY intervention
Description: STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
Study NCT06553287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01004 ointment 0.3%
Description: LNK01004 ointment 0.3% for topical application
Study NCT06553287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01004 ointment 1.0%
Description: LNK01004 ointment 1.0% for topical application
Study NCT06553287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01004 ointment 1.5%
Description: LNK01004 ointment 1.5% for topical application
Study NCT06553287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle BID
Description: Inactive vehicle matched to LNK01004 ointment for topical application.
Study NCT05505643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocare SlimLine Cryoprobe
Description: The Endocare(TM) SlimLine (TM) Cryoprobe is a single use, disposable device designed for use with Endocare Cryocare Surgical Systems. Endocare cryoprobes are designed to deliver cold temperatures for cryoablation using high-pressure argon gas circulated through the cryoprobe, followed by active thawing using helium gas.~The Cryocare CS Surgical System is intended for use in open, minimally invasive, or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery. The system is designed to freeze/ablate tissue by the application of extreme cold temperatures.
Study NCT05139095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib CohortA
Description: Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
Study NCT05139095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib Cohort B
Description: Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\]; or EMA/EP \[etoposide, methotrexate and actinomycin-D/etoposide, cisplatin\]; or FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]). The observation period is 21 days.
Study NCT05505643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy
Description: Patients randomized to cryoablation who experience disease recurrence may undergo crossover to lumpectomy.
Study NCT05505643 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumpectomy
Description: Patients randomized to cryoablation who experience disease recurrence may undergo crossover to lumpectomy.
Study NCT05192278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.
Study NCT04940078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
Study NCT04940078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
Study NCT04940078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide and semaglutide
Description: Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
Study NCT05175508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days
Study NCT05175508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid
Description: ATRA 20mg tid by po on days 1-21 of every cycle 28 days
Study NCT05578352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Add oral hyppoglycemia drug
Description: Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
Study NCT05578352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Add GLP-1 receptor agonist
Description: Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
Study NCT05578352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change insulin
Description: Change premix insulin to long-acting insulin
Study NCT05104905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexmarilimab
Description: A single neoadjuvant dose will be administered prior to surgery.
Study NCT05582317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
Study NCT05582317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
Study NCT06260696 — intervention group
Intervention type: OTHER
Intervention: No treatment is given
Description: No treatment is given
Study NCT06076434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region
Description: The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).
Study NCT04744779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Office-based accommodative/vergence therapy and home reinforcement
Description: Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
Study NCT05653739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Intervention
Description: MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
Study NCT06095375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.